| 000 | 01260 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515222052.0 | ||
| 264 | 0 | _c20100517 | |
| 008 | 201005s 0 0 ger d | ||
| 022 | _a1439-4413 | ||
| 024 | 7 |
_a10.1055/s-0030-1253679 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMüller-Wieland, D | |
| 245 | 0 | 0 |
_a[New, expensive antidiabetics for the treatment of type-2 diabetes--pro]. _h[electronic resource] |
| 260 |
_bDeutsche medizinische Wochenschrift (1946) _cMay 2010 |
||
| 300 |
_a922 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
| 650 | 0 | 4 |
_aCost-Benefit Analysis _xstatistics & numerical data |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 |
_aDrug Approval _xeconomics |
| 650 | 0 | 4 |
_aDrug Costs _xstatistics & numerical data |
| 650 | 0 | 4 | _aEvidence-Based Medicine |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemia _xblood |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadverse effects |
| 650 | 0 | 4 |
_aNational Health Programs _xeconomics |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tDeutsche medizinische Wochenschrift (1946) _gvol. 135 _gno. 18 _gp. 922 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1055/s-0030-1253679 _zAvailable from publisher's website |
| 999 |
_c19782567 _d19782567 |
||